🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Something for everyone! Published today in Nature Immunology 🎉 Our latest collab with Gavin Painter, Ian Hermans & others, packed with mRNA vaccines, TRM, liver immunity and preventing malaria. Doherty Institute UniMelb MDHS Malaghan Institute Ferrier Research Institute 🧵 👇 nature.com/articles/s4159…

Claudin 18.2 may be the anticancer target that enables CAR-T cell therapies and bispecific antibodies to tackle solid tumours, and more than 20 drug candidates from multiple modalities are now being developed to pursue it - read more in this news story go.nature.com/3OlMqGH

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions dlvr.it/SsZ0vF

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells dlvr.it/SsZjyP

Combined AAV-mediated gene replacement therapy improves auditory function in a mouse model of human DFNB42 deafness #genetherapy #celltherapy dlvr.it/SscwqH

Check out the recent letter @BloodJournal on the frst report of successful treatment of severe movement and neurocognitive toxicities (MNTs) post BCMA CAR-T 👇🏼 #CART Dr Marcela Maus Matthew Frigault doi.org/10.1182/blood.…

CAR T therapy beyond cancer! ✨ Daniel J. Baker alongside Carl June and team at Penn Medicine examine potential applications for CAR T therapy for a wide range of contexts. Learn more at nature: 📑 go.nature.com/3rPTsdO

A family of TRAF-binding endodomains that outperform benchmarks in primary NK cells along dimensions of persistence and cytotoxicity, even in low IL-2 conditions biorxiv.org/content/10.110…

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting Saul “Cancer Asskicker” Priceman nature.com/articles/s4146…

High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation Michael Birnbaum Brooke Huisman nature.com/articles/s4146…

Delighted to share our latest review of the next generation CAR T and NK cells for cancer immunotherapy in Immunological Reviews with Katy Rezvani, M.D., Ph.D and @Yl668Li ! Kudos to Ethan for his outstanding work on this! MD Anderson Cancer Center #NK #CAR onlinelibrary.wiley.com/doi/10.1111/im…

I don't know if that's the only root cause of tonic signaling but great work by $ELIC researchers. Makes sense wrt $ACLX eg who don't use scFv's but D-Domains. Complementarity-determining region clustering may cause CAR-T cell dysfunction nature.com/articles/s4146…

Speaking of ASTCT, from their weekly emails - a cool new Blood Advances paper about using IL-7 to boost CAR-NKT targeting BCMA in #MMsm models. Everything I've ever heard about CAR-NKT cells is fascinating - potentially the "Goldilocks" of IEC therapy! ashpublications.org/bloodadvances/…

Prolonged cytopenias following CAR T-cell therapy are a major challenge in LBCL. We identified a clonally-expanded population of effector CD8 T-cells expressing IFN-g in the bone marrow of these patients. #lmsm Xubin Li MD Anderson Cancer Center cell.com/cell-reports-m…

A #MMsm true crime podcast! MM cells downregulated BCMA overnight after BCMA CAR-T exposure but upregulated HLA... rendering them susceptible to BOB1 TCR-engineered cells waiting in wings. Cool LUMC Global pre-clinical work, now out in Blood Advances! ashpublications.org/bloodadvances/…

Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes #MTMCD dlvr.it/Str2ck

👏👏 Sequential administration of FAP-#CARTcell #immunotherapy then Meso-CAR T enhances systemic endogenous adaptive anti-tumor immunity in pancreatic #cancer models. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid

Albeena Nisar moderates the panel “Breaking Solid Barriers" Panelists Dr.Wayne Marasco, Avery Posey , Rajiv Khanna, Dr. Rajarshi Pal, Shailendra Upraity, PhD address solutions Gaurav Narula MD ACTREC-TMC Tata Memorial Hospital CAR-T & Cell Therapy Centre (CTCTC) ACTREC_TMC SIOP-Africa SIOP Asia ISCT Early Stage Professionals Committee Department of Biotechnology DBT-BIRAC

It’s been a long journey and many amazing people involved ! Exciting times ahead in the #CellularTherapy field !

Trispecific nanoAb targeting PDL1, 4-1BB, and NKG2A (or TIGIT) simultaneously, effectively triggers activation of NK and CD8+ T cells & tumor cell killing Nature Communications nature.com/articles/s4146…